Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522833 · ClinicalTrials.gov registry record
Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer
A clinical trial, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- 27
- Enrollment target
NCT01522833 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 27 participants.
The verdict
NCT01522833 has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the clinical characteristics that are associated with erlotinib-responders. Additionally, biopsy specimens from enrolled patient cases that are EGFR-wt will be evaluated via exploratory genetic analysis for correlated markers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-10 |
| Est. Completion | 2015-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522833
The ClinicalTrials.gov registry entry for NCT01522833 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01522833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522833 about?
NCT01522833 is a clinical study titled "Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer". With roughly 80% of cancer patients receiving their oncology care in the community setting, the investigators are proposing to sample from a community-based center to evaluate the percentage of epidermal growth factor receptor (EGFR)-wild type patients that gain benefit from erlotinib and assess the...
What is the current status of trial NCT01522833?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2012-10. Estimated completion is 2015-02.
Who is sponsoring clinical trial NCT01522833?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.